Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Jämförande studie av EnliTuo® före och efter teknologiförändring hos friska manliga volontärer

29 september 2026 uppdaterad av: Taizhou Mabtech Pharmaceutical Co.,Ltd

Randomiserad, dubbelblind, parallellkontrollerad, enkeldosfarmakokinetisk, säkerhets- och immunogenitetsjämförelsestudie av EnliTuo® före och efter teknisk förändring hos friska manliga volontärer

This study is a randomized, double-Blind, parallel-controlled, single-dose pharmacokinetic, safety, and immunogenicity comparative study of EnliTuo® before and after technology change in healthy male volunteers.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Faktisk)

86

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Shanghai, Kina
        • Shanghai Xuhui Central Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 45 år (Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Manlig

Beskrivning

Inclusion Criteria:

  • Healthy males aged ≥ 18 years and ≤ 45 years on the day of signing the informed consent form;
  • At screening, body weight ≥ 50 kg and ≤ 80 kg, with a Body Mass Index (BMI) between 19.0 and 26.0 kg/m² (inclusive of boundary values);
  • Capable of understanding the study, including its purpose, research procedures, potential risks, etc., and able to communicate well with researchers and complete the study in accordance with the study requirements;
  • Voluntarily sign the informed consent form.

Exclusion Criteria:

  • Subjects with any abnormally clinically significant findings in comprehensive examinations (vital signs, physical examination, electrocardiogram, chest X-ray, abdominal ultrasound, blood routine, urine routine, blood biochemistry, coagulation, etc.) as judged by the investigator;
  • Subjects with a history of major diseases in the cardiovascular, endocrine, nervous, digestive, respiratory, genitourinary, hematological, immune, or mental systems, or currently suffering from any disease in the above systems;
  • Subjects with a known or suspected history of keratitis, ulcerative keratitis, conjunctivitis, blepharitis, or severe dry eye;
  • Subjects with hereditary bleeding tendency, coagulation dysfunction, or a history of thrombotic or hemorrhagic diseases;
  • Subjects with active infections requiring systemic treatment;
  • Subjects positive for any of HBV surface antigen, HCV antibody, HIV antibody, or Treponema pallidum antibody;
  • Subjects with a history of malignant tumors within the past 5 years, except for completely resected in-situ cutaneous basal cell carcinoma or squamous cell carcinoma;
  • Subjects who have undergone surgical operations within 4 weeks before screening, or plan to undergo surgery during the trial period;
  • Subjects who have used any prescription drugs, over-the-counter drugs, traditional Chinese medicines, proprietary Chinese medicines, health supplements, etc., within 4 weeks before screening, or whose use of the above substances has not exceeded 5 half-lives (whichever is longer);
  • Subjects who have used any biological products or received any vaccines within 12 weeks before screening, or plan to receive any vaccines during the study period;
  • Subjects currently enrolled in other clinical studies of drugs or medical devices, or whose time since the end of the last enrolled clinical study is less than 12 weeks, or whose time since the last trial drug administration has not exceeded 5 half-lives (whichever is longer);
  • Subjects positive for anti-drug antibodies against anti-epidermal growth factor receptor antibodies;
  • Subjects with substance abuse, or who have used soft drugs within 3 months before screening or hard drugs within 1 year before screening; or who consume excessive tea, coffee, and/or caffeinated beverages daily (more than 8 cups, 1 cup = 250 mL); or who have a positive urine drug screen;
  • Subjects with alcoholism, or whose weekly alcohol consumption exceeds 14 units within 3 months before screening (1 unit = 17.7 mL ethanol, i.e., 1 unit = 357 mL of beer with 5% alcohol content, 43 mL of liquor with 40% alcohol content, or 147 mL of wine with 12% alcohol content); or who have a positive alcohol breath test; and those who cannot cooperate with alcohol prohibition during the study;
  • Subjects who smoked more than 10 cigarettes per day on average within 6 months before screening;
  • Subjects who engaged in strenuous activities within 72 hours before drug administration, or cannot avoid strenuous activities during the study; or have other physiological or pathological conditions that may affect the absorption, distribution, metabolism, or excretion of the study drug;
  • Subjects who have donated blood (including component blood) or lost more than 400 mL of blood, or received blood transfusions within 3 months before screening; or donated blood (including component blood) or lost more than 200 mL of blood within 1 month before screening;
  • Subjects with a known history of allergy to the active ingredient or any excipient of the study drug, or to other biological products; or with a history of atopic allergic diseases (e.g., asthma, urticaria, eczematous dermatitis, etc.); or with allergic diathesis;
  • Subjects who cannot tolerate venipuncture or have a history of fainting due to needle or blood;
  • Subjects with special dietary requirements who cannot accept the diet provided by the clinical trial center;
  • Subjects who cannot take effective contraceptive measures or plan to donate sperm within 3 months after the administration of the study drug;
  • Other conditions deemed by the investigator to make the subject unsuitable for participating in this study.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: New technology Enlituo

treated with new technology Enlituo through single intravenous drip

250 mg/m^2, single intravenous drip

Aktiv komparator: Approved technology Enlituo

treated with Approved technology Enlituo through single intravenous drip

250 mg/m^2, single intravenous drip

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
AUC0-∞
Tidsram: From enrollment to the end of treatment at 28 days

Area under the concentration time curve extrapolated to infinity

From enrollment to the end of treatment at 28 days

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
AUC0-t
Tidsram: From enrollment to the end of treatment at 28 days

Area under the concentration time curve from time zero to the last measurable time point.

From enrollment to the end of treatment at 28 days
Cmax
Tidsram: From enrollment to the end of treatment at 28 days

Peak concentration.

From enrollment to the end of treatment at 28 days
Tmax
Tidsram: From enrollment to the end of treatment at 28 days

time to peak

From enrollment to the end of treatment at 28 days
t1/2
Tidsram: From enrollment to the end of treatment at 28 days

half-life

From enrollment to the end of treatment at 28 days
λz
Tidsram: From enrollment to the end of treatment at 28 days

Terminal Elimination Rate Constant

From enrollment to the end of treatment at 28 days
CL
Tidsram: From enrollment to the end of treatment at 28 days

clearance

From enrollment to the end of treatment at 28 days
Vd
Tidsram: From enrollment to the end of treatment at 28 days

volume of distribution

From enrollment to the end of treatment at 28 days
Immunogenicity
Tidsram: From enrollment to the end of treatment at 28 days

Anti-drug antibody positive rate

From enrollment to the end of treatment at 28 days
Adverse Event
Tidsram: From enrollment to the end of treatment at 6 months

Incidence and Severity of Adverse Events

From enrollment to the end of treatment at 6 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Jingying Jia, PhD, Xuhui Central Hospital, Shanghai

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

11 november 2025

Primärt slutförande (Faktisk)

14 april 2026

Avslutad studie (Faktisk)

14 april 2026

Studieregistreringsdatum

Först inskickad

17 november 2025

Först inskickad som uppfyllde QC-kriterierna

17 november 2025

Första postat (Faktisk)

24 november 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

30 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

29 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Nyckelord

Andra studie-ID-nummer

  • CMAB009-C-102

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

After the study result is published, email the application registration contact or the study leader to obtain it.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera